The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

In a separate development, Jefferies has downgraded GSK from 'Buy' to 'Hold', citing potential headwinds for Arexvy & Shingrix, and the US Medicare Part D redesign. Despite this, Jefferies ...

with key product Shingrix falling. RSV vaccine Arexvy collapsed 72% due to US guideline changes and the prior-year launch boost fading. If this trend continues in the full-year results ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK's Recombinant Zoster ...

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...

GSK said that IDRX-42 addresses all the key ... as well as competition to shingles vaccine Shingrix, currently its top product, from the likes of Pfizer/BioNTech and Moderna.